Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

Per the Zacks analyst, amid a volatile macro environment, the company is making significant strides in Business AI initiatives ... are featuring today include Boston Scientific Corp. (BSX), Sanofi ...

AusBiotech is honoured to announce the establishment of the Depaz Oration, an annual keynote to be introduced at the AusBiotech Conference in 2025 in ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: ...

underscored by a billion-dollar partnership with Sanofi. This collaboration is unique, focusing not on a specific drug but on ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Neuraxpharm has successfully scaled its portfolio of well-known brands, not only through the acquisition of more than 30 established global CNS brands from Sanofi in 2022 but, more recently, through ...

Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...